EXTH-79. BEVACIZUMAB IRINOTECAN TEMOZOLOMIDE TYROSINE KINASE INHIBITION AND MEK INHIBITION ARE EFFECTIVE AGAINST PLEOMORPHIC XANTHOASTROCYTOMA REGARDLESS OF V600E STATUS

摘要

BACKGROUNDPleomorphic xanthoastrocytoma (PXA) is a rare Grade II and III glioma. Surgical resection is the mainstay of treatment; however, adjuvant therapy is sometimes necessary. Given the rarity of PXA, chemotherapeutic efficacy data is limited. The importance of the BRAF V600E mutation in the context of MAP kinase pathway inhibition is unknown. The purpose of this study was to perform an in vivo screen of a variety to agents to determine efficacy against both V600E mutant and non-mutant PXA.